Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with TACE for unresectable colorectal cancer liver metastases after surgery
ChiCTR1800016360Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in colorectal cancer (CRC), sponsored by Changhai Hospital. Primary endpoint: time to progression. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR1800016360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016360.